Your browser doesn't support javascript.
loading
Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021.
Rogier, Eric; Battle, Nastassia; Bakari, Catherine; Seth, Misago D; Nace, Douglas; Herman, Camelia; Barakoti, Achut; Madebe, Rashid A; Mandara, Celine I; Lyimo, Beatus M; Giesbrecht, David J; Popkin-Hall, Zachary R; Francis, Filbert; Mbwambo, Daniel; Garimo, Issa; Aaron, Sijenunu; Lusasi, Abdallah; Molteni, Fabrizio; Njau, Ritha; Cunningham, Jane A; Lazaro, Samwel; Mohamed, Ally; Juliano, Jonathan J; Bailey, Jeffrey A; Udhayakumar, Venkatachalam; Ishengoma, Deus S.
Afiliación
  • Rogier E; Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Battle N; CDC Foundation, Atlanta, GA, USA.
  • Bakari C; National Institute for Medical Research, Dar Es Salaam, Tanzania.
  • Seth MD; National Institute for Medical Research, Dar Es Salaam, Tanzania.
  • Nace D; Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Herman C; Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Barakoti A; Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Madebe RA; CDC Foundation, Atlanta, GA, USA.
  • Mandara CI; National Institute for Medical Research, Dar Es Salaam, Tanzania.
  • Lyimo BM; National Institute for Medical Research, Dar Es Salaam, Tanzania.
  • Giesbrecht DJ; National Institute for Medical Research, Dar Es Salaam, Tanzania.
  • Popkin-Hall ZR; Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania.
  • Francis F; Brown University, Providence, RI, USA.
  • Mbwambo D; University of North Carolina, Chapel Hill, NC, USA.
  • Garimo I; National Institute for Medical Research, Tanga, Tanzania.
  • Aaron S; National Malaria Control Programme, Dodoma, Tanzania.
  • Lusasi A; National Malaria Control Programme, Dodoma, Tanzania.
  • Molteni F; National Malaria Control Programme, Dodoma, Tanzania.
  • Njau R; National Malaria Control Programme, Dodoma, Tanzania.
  • Cunningham JA; Swiss Tropical Public Health Institute, Dar Es Salaam, Tanzania.
  • Lazaro S; World Health Organization, Country Office, Dar Es Salaam, Tanzania.
  • Mohamed A; World Health Organization, Headquarters, Geneva, Switzerland.
  • Juliano JJ; National Malaria Control Programme, Dodoma, Tanzania.
  • Bailey JA; National Malaria Control Programme, Dodoma, Tanzania.
  • Udhayakumar V; University of North Carolina, Chapel Hill, NC, USA.
  • Ishengoma DS; Brown University, Providence, RI, USA.
Sci Rep ; 14(1): 8158, 2024 04 08.
Article en En | MEDLINE | ID: mdl-38589477
ABSTRACT
Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health Organization (WHO) recommends switching to a non-HRP2 RDT for P. falciparum clinical case diagnosis when pfhrp2 deletion prevalence causes ≥ 5% of RDTs to return false negative results. Tanzania is a country of heterogenous P. falciparum transmission, with some regions approaching elimination and others at varying levels of control. In concordance with the current recommended WHO pfhrp2 deletion surveillance strategy, 100 health facilities encompassing 10 regions of Tanzania enrolled malaria-suspected patients between February and July 2021. Of 7863 persons of all ages enrolled and providing RDT result and blood sample, 3777 (48.0%) were positive by the national RDT testing for Plasmodium lactate dehydrogenase (pLDH) and/or HRP2. A second RDT testing specifically for the P. falciparum LDH (Pf-pLDH) antigen found 95 persons (2.5% of all RDT positives) were positive, though negative by the national RDT for HRP2, and were selected for pfhrp2 and pfhrp3 (pfhrp2/3) genotyping. Multiplex antigen detection by laboratory bead assay found 135/7847 (1.7%) of all blood samples positive for Plasmodium antigens but very low or no HRP2, and these were selected for genotyping as well. Of the samples selected for genotyping based on RDT or laboratory multiplex result, 158 were P. falciparum DNA positive, and 140 had sufficient DNA to be genotyped for pfhrp2/3. Most of these (125/140) were found to be pfhrp2+/pfhrp3+, with smaller numbers deleted for only pfhrp2 (n = 9) or only pfhrp3 (n = 6). No dual pfhrp2/3 deleted parasites were observed. This survey found that parasites with these gene deletions are rare in Tanzania, and estimated that 0.24% (95% confidence interval 0.08% to 0.39%) of false-negative HRP2-RDTs for symptomatic persons were due to pfhrp2 deletions in this 2021 Tanzania survey. These data provide evidence for HRP2-based diagnostics as currently accurate for P. falciparum diagnosis in Tanzania.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígenos de Grupos Sanguíneos / Malaria Falciparum Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígenos de Grupos Sanguíneos / Malaria Falciparum Límite: Humans País/Región como asunto: Africa Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos